peptide-based immunotherapy

This page covers all peptide-based immunotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting myelin-associated glycoprotein (MAG).

Targets

myelin-associated glycoprotein (MAG)

Phase 2 pipeline (1)

• ATX-MS-1467 · Apitope Technology (Bristol) Ltd. · Immunology
  ATX-MS-1467 is a peptide-based immunotherapy targeting myelin-associated glycoprotein (MAG) to treat multiple sclerosis.

Patent intelligence

• peptide based immunotherapy patent landscape — aggregated cliff calendar, attackable patents, originator estates